This sustained tumor shrinkage is observed in both benign and malignant tumors associated with different neurofibromatosis subtypes, including NF1, NF2, and schwannomatosis, highlighting the drug’s broad therapeutic potential. The gene discussed is NF2; the disease is neurofibromatosis.